Compare Becton Dickinson and Co (BDX) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Under Armour Inc Class A — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Under Armour Inc Class A trades at $5.24 (market cap $2.48B). The key difference: Becton Dickinson and Co is far larger — about 19.7× Under Armour Inc Class A's market cap, and Becton Dickinson and Co pays a 2.34% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| BDX | UA | |
|---|---|---|
Market Cap | $48.93B | $2.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $7.88 |
52-Week Low | $138.62 | $3.96 |
Enterprise Value | $65.03B | $3.46B |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Under Armour (UA) trades at $5.925, down 5.2% with bearish technical signals. The company reported mixed Q2 2026 results with an earnings beat but faces revenue declines and negative profitability metrics. Recent news highlights lowered fiscal 2027 revenue outlook due to softer consumer demand in key markets. Cash flow remains negative with significant operational challenges.
The outlook remains challenging with declining revenue trends and negative margins. While analyst consensus shows mixed sentiment, the stock faces headwinds from competitive pressures and execution risks. Investment opportunity exists only for those betting on a successful turnaround despite current fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
